A cross-sectional multicenter study of osteogenesis imperfecta in North America - results from the linked clinical research centers

Clinical Genetics

Volumn 87, Issue 2, 2015, Pages 133-140

  Patel, R M ^a   Nagamani, S C S ^a   Cuthbertson, D ^b   Campeau, P M ^a   Krischer, J P ^b   Shapiro, J R ^c   Steiner, R D ^d,e   Smith, P A ^f   Bober, M B ^g   Byers, P H ^h   Pepin, M ^h   Durigova, M ⁱ   Glorieux, F H ⁱ   Rauch, F ⁱ   Lee, B H ^a,j   Hart, T ^k   Sutton, V R ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c KENNEDY KRIEGER INSTITUTE   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^e University of Wisconsin   (United States)

^f SHRINERS HOSPITALS FOR CHILDREN   (United States)

^g NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

^h UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

ⁱ SHRINERS HOSPITAL FOR CHILDREN   (Canada)

^j HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^k Osteogenesis Imperfecta Foundation   (United States)

more..

Author keywords

Bone mineral density in osteogenesis imperfecta; History study; Longitudinal study; Natural history study; Osteogenesis imperfecta

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; COLLAGEN TYPE 1; ALPHA 2(I) COLLAGEN; COLLAGEN TYPE I, ALPHA 1 CHAIN;

ADOLESCENT; ADULT; AGED; ARTICLE; BONE DENSITY; BONE MASS; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FAMILY HISTORY; FEMALE; FRAMESHIFT MUTATION; HEARING IMPAIRMENT; HUMAN; INDEL MUTATION; INFANT; JOINT LAXITY; LONGITUDINAL STUDY; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; NEWBORN; NORTH AMERICA; OSTEOGENESIS IMPERFECTA; PREVALENCE; PRIORITY JOURNAL; SCOLIOSIS; TOOTH MALFORMATION; CLINICAL TRIAL; DIAGNOSTIC USE; GENETICS; MIDDLE AGED; MULTICENTER STUDY; MUTATION; PATHOPHYSIOLOGY; PRESCHOOL CHILD;

ADOLESCENT; ADULT; AGED; BONE DENSITY; CHILD; CHILD, PRESCHOOL; COLLAGEN TYPE I; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; MUTATION; NORTH AMERICA; OSTEOGENESIS IMPERFECTA;

EID: 84921435786     PISSN: 00099163     EISSN: 13990004     Source Type: Journal    
DOI: 10.1111/cge.12409     Document Type: Article

References (47)

1. Rauch F, Glorieux FH. Osteogenesis imperfecta. Lancet 2004: 363: 1377-1385.
2. Sillence DO, Senn A, Danks DM. Genetic heterogeneity in osteogenesis imperfecta. J Med Genet 1979: 16: 101-116.
3. Sykes B, Ogilvie D, Wordsworth P, Anderson, JN. Osteogenesis imperfecta is linked to both type I collagen structural genes. Lancet 1986: 2: 69-72.
4. Morello R, Bertin TK, Chen Y et al. CRTAP is required for prolyl 3- hydroxylation and mutations cause recessive osteogenesis imperfecta. Cell 2006: 127: 291-304.
5. Barnes AM, Chang W, Morello R et al. Deficiency of cartilage-associated protein in recessive lethal osteogenesis imperfecta. N Engl J Med 2006: 355: 2757-2764.
6. Cabral WA, Chang W, Barnes AM et al. Prolyl 3-hydroxylase 1 deficiency causes a recessive metabolic bone disorder resembling lethal/severe osteogenesis imperfecta. Nat Genet 2007: 39: 359-365.
7. van Dijk FS, Nesbitt IM, Zwikstra EH et al. PPIB mutations cause severe osteogenesis imperfecta. Am J Hum Genet 2009: 85: 521-527.
8. Christiansen HE, Schwarze U, Pyott SM et al. Homozygosity for a missense mutation in SERPINH1, which encodes the collagen chaperone protein HSP47, results in severe recessive osteogenesis imperfecta. Am J Hum Genet 2010: 86: 389-398.
9. Lapunzina P, Aglan M, Temtamy S et al. Identification of a frameshift mutation in Osterix in a patient with recessive osteogenesis imperfecta. Am J Hum Genet 2010: 87: 110-114.
10. Alanay Y, Avaygan H, Camacho N et al. Mutations in the gene encoding the RER protein FKBP65 cause autosomal-recessive osteogenesis imperfecta. Am J Hum Genet 2010: 86: 551-559.
11. Barnes AM, Carter EM, Cabral WA et al. Lack of cyclophilin B in osteogenesis imperfecta with normal collagen folding. N Engl J Med 2010: 362: 521-528.
12. Becker J, Semler O, Gilissen C et al. Exome sequencing identifies truncating mutations in human SERPINF1 in autosomal-recessive osteogenesis imperfecta. Am J Hum Genet 2011: 88: 362-371.
13. Martinez-Glez V, Valencia M, Caparros-Martin JA et al. Identification of a mutation causing deficient BMP1/mTLD proteolytic activity in autosomal recessive osteogenesis imperfecta. Hum Mutat 2012: 33: 343-350.
14. Shaheen R, Alazami AM, Alshammari MJ et al. Study of autosomal recessive osteogenesis imperfecta in Arabia reveals a novel locus defined by TMEM38B mutation. J Med Genet 2012: 49: 630-635.
15. Cho TJ, Lee KE, Lee SK et al. A single recurrent mutation in the 5′-UTR of IFITM5 causes osteogenesis imperfecta type V. Am J Hum Genet 2012: 91: 343-348.
16. Laine CM, Joeng KS, Campeau PM et al. WNT1 mutations in early-onset osteoporosis and osteogenesis imperfecta. N Engl J Med 2013: 368: 1809-1816.
17. Choi JW, Sutor SL, Lindquist L et al. Severe osteogenesis imperfecta in cyclophilin B-deficient mice. PLoS Genet 2009: 5: e1000750.
18. Fahiminiya S, Majewski J, Mort J et al. Mutations in WNT1 are a cause of osteogenesis imperfecta. J Med Genet 2013: 50: 345-348.
19. Keupp K, Beleggia F, Kayserili H et al. Mutations in WNT1 cause different forms of bone fragility. Am J Hum Genet 2013: 92: 565-574.
20. Pyott SM, Tran TT, Leistritz DF et al. WNT1 mutations in families affected by moderately severe and progressive recessive osteogenesis imperfecta. Am J Hum Genet 2013: 92: 590-597.
21. Semler O, Garbes L, Keupp K et al. A mutation in the 5′-UTR of IFITM5 creates an in-frame start codon and causes autosomal-dominant osteogenesis imperfecta type V with hyperplastic callus. Am J Hum Genet 2012: 91: 349-357.
22. Marini JC. Philadelphia: Saunders, 2004.
23. O'Leary M, Krailo M, Anderson JR, Reaman GH, Children's Oncology Group. Progress in childhood cancer: 50 years of research collaboration, a report from the Children's Oncology Group. Semin Oncol 2008: 35: 484-493.
24. Burns J, Ouvrier R, Estilow T et al. Validation of the Charcot-Marie-Tooth disease pediatric scale as an outcome measure of disability. Ann Neurol 2012: 71: 642-652.
25. Clowse ME, Richeson RL, Pieper C, Merkel PA, Vasculitis Clinical Research Consortium. Pregnancy outcomes among patients with vasculitis. Arthritis Care Res 2013: 65: 1370-1374.
26. Mistry PK. Rare disease clinical research network's urea cycle consortium delivers a successful clinical trial to improve alternate pathway therapy. Hepatology 2013: 57: 2100-2102.
27. Richesson RL, Sutphen R, Shereff D, Krischer JP. The Rare Diseases Clinical Research Network Contact Registry update: features and functionality. Contemp Clin Trials 2012: 33: 647-656.
28. Tuchman M, Lee B, Lichter-Konecki U et al. Cross-sectional multicenter study of patients with urea cycle disorders in the United States. Mol Genet Metab 2008: 94: 397-402.
29. Stone KL, Seeley DG, Lui LY et al. BMD at multiple sites and risk of fracture of multiple types: long-term results from the Study of Osteoporotic Fractures. J Bone Miner Res 2003: 18: 1947-1954.
30. Johnell O, Kanis JA, Oden A et al. Predictive value of BMD for hip and other fractures. J Bone Miner Res 2005: 20: 1185-1194.
31. Leslie WD, Tsang JF, Caetano PA, Lix LM, Manitoba Bone Density Program. Effectiveness of bone density measurement for predicting osteoporotic fractures in clinical practice. J Clin Endocrinol Metab 2007: 92: 77-81.
32. Black DM, Cummings SR, Genant HK, Nevitt MC, Palermo L, Browner W. Axial and appendicular bone density predict fractures in older women. J Bone Miner Res 1992: 7: 633-638.
33. Cauley JA, Hochberg MC, Lui LY et al. Long-term risk of incident vertebral fractures. JAMA 2007: 298: 2761-2767.
34. Adami S, Gatti D, Colapietro F et al. Intravenous neridronate in adults with osteogenesis imperfecta. J Bone Miner Res 2003: 18: 126-130.
35. Chevrel G, Schott AM, Fontanges E et al. Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3-year randomized placebo-controlled trial. J Bone Miner Res 2006: 21: 300-306.
36. Gatti D, Antoniazzi F, Prizzi R et al. Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study. J Bone Miner Res 2005: 20: 758-763.
37. Phillipi CA, Remmington T, Steiner RD. Bisphosphonate therapy for osteogenesis imperfecta. Cochrane Database Syst Rev 2008: CD005088.
38. Public Law 98-551. Health Promotion and Disease Prevention Amendments of 1984. October 30, 1984.
39. Diaz GA, Krivitzky LS, Mokhtarani M et al. Ammonia control and neurocognitive outcome among urea cycle disorder patients treated with glycerol phenylbutyrate. Hepatology 2013: 57: 2171-2179.
40. Nagamani SC, Shchelochkov OA, Mullins MA et al. A randomized controlled trial to evaluate the effects of high-dose versus low-dose of arginine therapy on hepatic function tests in argininosuccinic aciduria. Mol Genet Metab 2012: 107: 315-321.
41. Majorana A, Bardellini E, Brunelli PC, Lacaita M, Cazzolla AP, Favia G. Dentinogenesis imperfecta in children with osteogenesis imperfecta: a clinical and ultrastructural study. International journal of paediatric dentistry/the British Paedodontic Society [and] the International Association of Dentistry for. Children 2010: 20: 112-118.
42. Malmgren B, Norgren S. Dental aberrations in children and adolescents with osteogenesis imperfecta. Acta Odontol Scand 2002: 60: 65-71.
43. O'Connell A, Marini J. Evaluation of oral problems in an osteogenesis imperfecta population. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1999: 87: 189-196.
44. Shapiro JR, Lietman C, Grover M et al. Phenotypic variability of osteogenesis imperfecta type V caused by an IFITM5 mutation. J Bone Miner Res 2013: 28: 1523-1530.
45. Kuurila K, Kaitila I, Johansson R, Grenman R. Hearing loss in Finnish adults with osteogenesis imperfecta: a nationwide survey. Ann Otol Rhinol Laryngol 2002: 111: 939-946.
46. Shapiro JR, Pikus A, Weiss G, Rowe DW. Hearing and middle ear function in osteogenesis imperfecta. JAMA 1982: 247: 2120-2126.
47. Rauch F, Lalic L, Roughley P, Glorieux FH. Relationship between genotype and skeletal phenotype in children and adolescents with osteogenesis imperfecta. J Bone Miner Res 2010: 25: 1367-1374.